Studies have reported that ferroptosis inducers (such as RSL3, erastin, sorafenib, and sulfasalazine) can enhance the effectiveness of radiotherapy by inhibiting SLC7A11 or inactivating GPX4 in tumor models such as glioma, lung cancer, fibrosarcoma, melanoma, breast cancer, and cervical cancer [9,11,12,13,14]. The gene discussed is GPX4; the disease is neoplasm.